Brief: Kintor Pharmaceutical Says U.S. FDA Has Approved Proxalutamide's Phase Iii Covid-19 Clinical Trial
05/03/2021 08:23
March 5 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* U.S. FDA HAS APPROVED PROXALUTAMIDE'S PHASE III COVID-19
CLINICAL TRIAL
Source text for Eikon: urn:newsml:reuters.com:*:nHKSw2Ryj
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint